- Editor’s Note on Recent Journal Impact Factor of Cancer Research and Treatment
-
Ahn YC
- KMID: 2557658
- Cancer Res Treat.
- 2024 Jul;56(3):699-699.
- doi: 10.4143/crt.2024.619
-
- CITED
-
- Close
- SHARE
-
- Close
- Bridging the Gap between Trial Adverse Events and Real-World Data
-
Kim SH, Lee H, Park DW
- KMID: 2557684
- Cancer Res Treat.
- 2024 Jul;56(3):972-973.
- doi: 10.4143/crt.2024.019
-
- CITED
-
- Close
- SHARE
-
- Close
- HER2-Low Breast Cancer: Now and in the Future
-
Kang S, Kim SB
- KMID: 2557659
- Cancer Res Treat.
- 2024 Jul;56(3):700-720.
- doi: 10.4143/crt.2023.1138
Breast cancer is a heterogeneous disease, and its subtypes are characterized by hormone receptor and human epidermal growth factor receptor 2 (HER2) expression status. “HER2-low” tumors, which exhibit a low... -
- CITED
-
- Close
- SHARE
-
- Close
- Trastuzumab Biosimilar (HLX02), Pertuzumab Plus Chemotherapy in Patients with HER2-Positive Metastatic Breast Cancer after Progression of Trastuzumab: A Prospective, Phase II Study
-
Zhang R, Liu X, Song G, Zhang Y, Li H
- KMID: 2557666
- Cancer Res Treat.
- 2024 Jul;56(3):795-801.
- doi: 10.4143/crt.2023.1151
Purpose This study aims to evaluate the efficacy and safety of trastuzumab biosimilar (HLX02) in combination with pertuzumab and chemotherapy in patients with human epidermal growth factor receptor 2 (HER2)–positive... -
- CITED
-
- Close
- SHARE
-
- Close
- Molecular and Treatment Characteristics of SMARCB1 or SMARCA4-Deficient Undifferentiated Tumor: Retrospective Case Series
-
Kang HG, Koh J, Kim TM, Han DH, Won TB, Kim DW, Kim DY, Keam B
- KMID: 2557683
- Cancer Res Treat.
- 2024 Jul;56(3):967-971.
- doi: 10.4143/crt.2023.1308
SMARCB1 or SMARCA4-deficient sinonasal carcinoma or thoracic undifferentiated tumor has aggressive nature with a poor prognosis. Patients with this disease were diagnosed by immunohistochemistry or next-generation sequencing. Those who were... -
- CITED
-
- Close
- SHARE
-
- Close
- Global Expanded Access Program for Pemigatinib in Patients with Previously Treated Locally Advanced or Metastatic Cholangiocarcinoma and Fibroblast Growth Factor Receptor Gene Alterations
-
Lindley A, Prager G, Bitzer M, Burn TC, Lihou CF, Croft E
- KMID: 2557671
- Cancer Res Treat.
- 2024 Jul;56(3):847-855.
- doi: 10.4143/crt.2023.1197
Purpose Pemigatinib is a fibroblast growth factor receptor-2 (FGFR2) inhibitor approved for use in patients with previously treated cholangiocarcinoma (CCA) and FGFR2 fusions or rearrangements. This ongoing global Expanded Access... -
- CITED
-
- Close
- SHARE
-
- Close
- Implementation of BRCA Test among Young Breast Cancer Patients in South Korea: A Nationwide Cohort Study
-
Hwang YH, Yoo TK, Lee SB, Kim J, Ko BS, Kim HJ, Lee JW, Son BH, Chung IY
- KMID: 2557667
- Cancer Res Treat.
- 2024 Jul;56(3):802-808.
- doi: 10.4143/crt.2023.1186
Purpose This study aimed to investigate the frequency of BRCA testing and related factors among young breast cancer patients (age < 40 years) in South Korea. Materials and Methods We conducted... -
- CITED
-
- Close
- SHARE
-
- Close
- Secondary Malignancies in Multiple Myeloma in Korean Patients: A Nationwide Population-Based Study
-
Park B, Lee E, Yoon J, Park Y, Eom HS
- KMID: 2557680
- Cancer Res Treat.
- 2024 Jul;56(3):936-944.
- doi: 10.4143/crt.2023.843
Purpose This study investigated the incidence of secondary malignancy in multiple myeloma (MM) patients compared with that in the general population using a population-based database covering all residents in Korea. Materials... -
- CITED
-
- Close
- SHARE
-
- Close
- Predicted Cervical Cancer Prevention: Impact of National HPV Vaccination Program on Young Women in South Korea
-
Kwak K, Hwang Ss
- KMID: 2557677
- Cancer Res Treat.
- 2024 Jul;56(3):898-908.
- doi: 10.4143/crt.2023.981
Purpose This study aimed to evaluate the effectiveness of the national human papillomavirus (HPV) vaccination program of South Korea among its entire female population, particularly among younger age groups. Materials and... -
- CITED
-
- Close
- SHARE
-
- Close
- The Persistence of Hypertriglyceridemia and the Risk of Early Onset Colorectal Cancer According to Tumor Subsites: A Nationwide Population-Based Study
-
Chang YH, Shin CM, Han K, Jung JH, Jin EH, Lim JH, Kang SJ, Choi YJ, Yoon H, Park YS, Kim N, Lee DH
- KMID: 2557669
- Cancer Res Treat.
- 2024 Jul;56(3):825-837.
- doi: 10.4143/crt.2023.753
Purpose The incidence of early-onset colorectal cancer (EoCRC) is increasing worldwide. The association between hypertriglyceridemia (HTG) and EoCRC risk remains unclear. Materials and Methods We conducted a nationwide cohort study of 3,340,635 individuals... -
- CITED
-
- Close
- SHARE
-
- Close
- The Clinical Efficacy of Colorectal Cancer Patients with Pulmonary Oligometastases by Sterotactic Body Ablative Radiotherapy: A Meta-Analysis
-
Jeong JU, Rim CH, Yoo GS, Cho WK, Chie EK, Ahn YC, Lee JH, on behalf of Korean Oligometastasis Working Group, Korean Cancer Association
- KMID: 2557668
- Cancer Res Treat.
- 2024 Jul;56(3):809-824.
- doi: 10.4143/crt.2023.920
Purpose There is increasing interest in the efficacy of stereotactic ablative radiotherapy (SABR) for treating colorectal cancer (CRC) patients with oligometastases (OM), recently. The purpose of this meta-analysis was to evaluate... -
- CITED
-
- Close
- SHARE
-
- Close
- CD19-Specific CAR-T Cell Treatment of 115 Children and Young Adults with Acute B Lymphoblastic Leukemia: Long-term Follow-up
-
Wang Y, Xue Yj, Zuo Yx, Jia Yp, Lu Ad, Zeng Hm, Zhang Lp
- KMID: 2557681
- Cancer Res Treat.
- 2024 Jul;56(3):945-955.
- doi: 10.4143/crt.2023.1205
Purpose Chemotherapy has been the primary treatment for patients with B-cell acute lymphoblastic leukemia (B-ALL). However, there are still patients who are not sensitive to chemotherapy, including those with refractory/relapse... -
- CITED
-
- Close
- SHARE
-
- Close
- Bilateral Seminal Vesicle Invasion as a Strong Prognostic Indicator in T3b Prostate Cancer Patients Following Radical Prostatectomy: A Comprehensive, Multicenter, Long-term Follow-up Study
-
Suh J, Jeong IG, Jeon HG, Jeong CW, Lee S, Jeon SS, Byun SS, Kwak C, Ahn H
- KMID: 2557675
- Cancer Res Treat.
- 2024 Jul;56(3):885-892.
- doi: 10.4143/crt.2023.1264
Purpose Pathologic T3b (pT3b) prostate cancer, characterized by seminal vesicle invasion (SVI), exhibits variable oncological outcomes post–radical prostatectomy (RP). Identifying prognostic factors is crucial for patient-specific management. This study investigates... -
- CITED
-
- Close
- SHARE
-
- Close
- Comparison of Clinicopathogenomic Features and Treatment Outcomes of EGFR and HER2 Exon 20 Insertion Mutations in Non–Small Cell Lung Cancer: Single-Institution Experience
-
Lee SH, Jeong H, Kim DH, Jang SJ, Kim SW, Yoon S, Lee DH
- KMID: 2557664
- Cancer Res Treat.
- 2024 Jul;56(3):774-784.
- doi: 10.4143/crt.2023.1177
Purpose Exon 20 insertion mutations (E20ins) in epidermal growth factor receptor (EGFR) or human epidermal growth factor receptor 2 (HER2) in non–small cell lung cancer (NSCLC) patients has become more... -
- CITED
-
- Close
- SHARE
-
- Close
- Phase 1/2a Study of Rivoceranib, a Selective VEGFR-2 Angiogenesis Inhibitor, in Patients with Advanced Solid Tumors
-
Kang YK, Ryu MH, Hong YS, Choi CM, Kim TW, Ryoo BY, Kim JE, Weis JR, Kingsford R, Park CH, Jang S, McGinn A, Werner TL, Sharma S
- KMID: 2557661
- Cancer Res Treat.
- 2024 Jul;56(3):743-750.
- doi: 10.4143/crt.2023.980
Purpose This study aimed to report the results from an early-phase study of rivoceranib, an oral tyrosine kinase inhibitor highly selective for vascular endothelial growth factor receptor 2, in patients... -
- CITED
-
- Close
- SHARE
-
- Close
- Association of Immune-Related Adverse Events and the Efficacy of Anti–PD-(L)1 Monotherapy in Non–Small Cell Lung Cancer: Adjusting for Immortal-Time Bias
-
Yu Y, Chen N, Yu S, Shen W, Zhai W, Li H, Fan Y
- KMID: 2557662
- Cancer Res Treat.
- 2024 Jul;56(3):751-764.
- doi: 10.4143/crt.2023.1118
Purpose The association between immune-related adverse events (irAEs) and survival outcomes in non–small cell lung cancer (NSCLC) patients treated with programmed death-(ligand) 1 [PD-(L)1] inhibitors remains controversial, partly due to... -
- CITED
-
- Close
- SHARE
-
- Close
- Analytical and Clinical Validation of a Highly Sensitive NGS-Based ctDNA Assay with Real-World Concordance in Non–Small Cell Lung Cancer
-
Yi H, Youk J, Lim Y, Roh H, Kyung D, Kim HP, Bang D, Keam B, Kim TM, Kim M, Kim DW, Kim TY
- KMID: 2557663
- Cancer Res Treat.
- 2024 Jul;56(3):765-773.
- doi: 10.4143/crt.2023.1294
Purpose There have been needs to improve the sensitivity of liquid biopsy. This report aims to report the analytical and clinical validation of a next-generation sequencing (NGS)–based circulating tumor DNA... -
- CITED
-
- Close
- SHARE
-
- Close
- Invasiveness of Upper Tract Urothelial Carcinoma: Clinical Significance and Integrative Diagnostic Strategy
-
Ahn B, Kim D, Park KJ, Park JM, Yoon SY, Hong B, Cho YM, Kim D
- KMID: 2557672
- Cancer Res Treat.
- 2024 Jul;56(3):856-870.
- doi: 10.4143/crt.2023.1150
Purpose In this study, we aimed to determine the clinicopathologic, radiologic, and molecular significance of the tumor invasiveness to further stratify the patients with high-grade (HG) upper tract urothelial carcinoma... -
- CITED
-
- Close
- SHARE
-
- Close
- The Role of Early and Delayed Surgery for Infants with Congenital Brain Tumors
-
Lee JS, Lee JY, Kim KH, Park SH, Koh EJ, Kim SK, Phi JH
- KMID: 2557678
- Cancer Res Treat.
- 2024 Jul;56(3):909-919.
- doi: 10.4143/crt.2023.1174
Purpose The present study aimed to evaluate the role of early and delayed surgery in congenital brain tumors and analyze the clinical outcomes of infantile brain tumors. Materials and Methods We... -
- CITED
-
- Close
- SHARE
-
- Close
- Feasibility of Circulating Tumor DNA Analysis in Patients with Follicular Lymphoma
-
Yoon SE, Shin SH, Nam DK, Cho J, Kim WS, Kim SJ
- KMID: 2557679
- Cancer Res Treat.
- 2024 Jul;56(3):920-935.
- doi: 10.4143/crt.2023.869
Purpose The feasibility of sequencing circulating tumor DNA (ctDNA) in plasma as a biomarker to predict early relapse or poor prognosis in patients with follicular lymphoma (FL) receiving systemic immunochemotherapy... -
- CITED
-
- Close
- SHARE
-
- Close
